ASBM Presents at Festival of Biologics 2022 Europe From November 2nd-4th, ASBM representatives participated in the Festival of Biologics 2022 Europe, held in Basel, Switzerland. ASBM Advisory Board Chair Philip Schneider, MS, FASHP, FFIP gave a presentation entitled “Key Factors for Improving Sustainability in Biosimilar Markets”. The presentation reflected the findings from a recent webinar ASBM held […]
ASBM Presents at WHO 75th INN Consultation On October 18th, ASBM participated in the World Health Organization’s 75th Consultation on International Non-proprietary Names (INN) for Pharmaceutical Substances, held in Geneva, Switzerland. This was the nineteenth INN Consultation in which ASBM has participated. ASBM was represented by Executive Director Michael Reilly, Esq., and Advisory Board […]
EMA & HMA Declare All Biosimilars “Interchangeable”In a joint statement dated September 19th, 2022, the European Medicines Agency (EMA) and the Heads of Medicines Agencies declared that all biosimilars approved in the European Union are interchangeable with their reference medicines. According to the statement, “interchangeable” means “the biosimilar can be used instead of its reference product (or vice versa) or one biosimilar can […]
GaBI Publishes Summary of ASBM Webinar on Biosimilar Success Factors The Generics and Biosimilars Initiative (GaBI) has published a report on the first of two webinars the organization recently co-hosted with ASBM. The report summarizes the presentations from the June 29th webinar which examined “Key Factors for Successful Biosimilar Uptake in Europe, Canada and the US”. View the webinar here. The […]
ASBM Representatives Discuss Biosimilars on AI Arthritis Podcast On August 31st, several ASBM representatives joined Tiffany Westrich-Robertson, CEO of the International Foundation for Autoimmune & Autoinflammatory Diseases, to record an episode of the AI Arthritis Voices 360 podcast. The episode discussed examined policy issues surrounding biosimilars and how these affect patients. ASBM was represented in […]
REGISTRATION OPEN: July 20th ASBM/GaBI Webinar on Non-Medical Switching On July 20th, ASBM and the Generics and Biosimilar Initiative (GaBI) will co-host the second in a series of webinars about key biosimilar policy issues. The webinar is entitled “Non-Medical Switching of Biologicals/Biosimilars: Canada, Europe and the US: Overview of Non-Medical Switching Practices of Biologicals/Biosimilars in Different Regions […]
ASBM & GaBI Host Non-Medical Switching Webinar On July 20th, 2022 ASBM and the Generics and Biosimilars Initiative (GaBI) hosted a 2-hour webinar entitled “Non-Medical Switching of Biologicals and Biosimilars: Canada, Europe, and the US”. The two-hour event offered an overview of non-medical switching practices in different regions and focused on the importance of safeguarding the patient-physician relationship. […]
Registration Open for June 29th ASBM/GaBI Webinar on Biosimilar Success in Europe and US On June 29th, ASBM and the Generics and Biosimilars Initiative (GaBI) will host a webinar entitled “KEY FACTORS FOR SUCCESSFUL UPTAKE OF BIOSIMILARS: EUROPE AND THE US: measures taken for improving biosimilar uptake and the potential role of healthcare providers and […]
ASBM Submits Comments on Health Canada’s Biosimilar Handbook for HCPs On April 29th, ASBM submitted comments to Health Canada as part of a stakeholder consultation on its draft Handbook for healthcare professionals on biosimilar biologic drugs. ASBM’s comments focused on the Handbook’s mixed messaging surrounding biosimilar equivalence and switching, including language which implies inaccurately that Canada’s […]
Health Canada Opens Consultation on Biosimilar Handbook for Healthcare Professionals Health Canada has opened a consultation on its draft Handbook for healthcare professionals on biosimilar biologic drugs. This publication was developed for the purpose of informing and educating healthcare professionals in Canada regarding biosimilars. The handbook was developed in consultation with a working group composed of […]
